These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 22795768)
21. Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. Berry RW; Sweet AP; Clark FA; Lagalwar S; Lapin BR; Wang T; Topgi S; Guillozet-Bongaarts AL; Cochran EJ; Bigio EH; Binder LI J Neurocytol; 2004 May; 33(3):287-95. PubMed ID: 15475684 [TBL] [Abstract][Full Text] [Related]
22. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897 [TBL] [Abstract][Full Text] [Related]
23. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644 [TBL] [Abstract][Full Text] [Related]
24. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Jellinger KA Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518 [TBL] [Abstract][Full Text] [Related]
25. [Neurofibrillary changes and phosphorylated tau of Alzheimer's disease]. Takeda M; Kudo T; Taniguchi N; Nishimura T Nihon Ronen Igakkai Zasshi; 1996 Mar; 33(3):169-72. PubMed ID: 8648891 [No Abstract] [Full Text] [Related]
26. Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. Mohorko N; Repovs G; Popović M; Kovacs GG; Bresjanac M J Neuropathol Exp Neurol; 2010 Apr; 69(4):405-14. PubMed ID: 20448485 [TBL] [Abstract][Full Text] [Related]
27. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies. Chalmers KA; Love S J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683 [TBL] [Abstract][Full Text] [Related]
28. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169 [TBL] [Abstract][Full Text] [Related]
29. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Thal DR; Holzer M; Rüb U; Waldmann G; Günzel S; Zedlick D; Schober R Exp Neurol; 2000 May; 163(1):98-110. PubMed ID: 10785448 [TBL] [Abstract][Full Text] [Related]
30. Progressive supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case. Mochizuki A; Ueda Y; Komatsuzaki Y; Tsuchiya K; Arai T; Shoji S Acta Neuropathol; 2003 Jun; 105(6):610-4. PubMed ID: 12669238 [TBL] [Abstract][Full Text] [Related]
31. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Gibb GM; de Silva R; Revesz T; Lees AJ; Anderton BH; Hanger DP Brain Res Mol Brain Res; 2004 Feb; 121(1-2):95-101. PubMed ID: 14969740 [TBL] [Abstract][Full Text] [Related]
32. [Neuropathology of corticobasal degeneration]. Wakabayashi K; Takahashi H No To Shinkei; 1996 Jun; 48(6):521-32. PubMed ID: 8703555 [No Abstract] [Full Text] [Related]
33. The relationship between histopathological features of progressive supranuclear palsy and disease duration. Josephs KA; Mandrekar JN; Dickson DW Parkinsonism Relat Disord; 2006 Mar; 12(2):109-12. PubMed ID: 16337422 [TBL] [Abstract][Full Text] [Related]
34. Correspondence regarding: selective deposition of 4-repeat tau in cerebral infarcts. J Neuropathol Exp Neurol 2009;68:1029-36. Kasahata N; Miyazawa Y; Kamei T J Neuropathol Exp Neurol; 2010 Mar; 69(3):321; author reply 321. PubMed ID: 20190609 [No Abstract] [Full Text] [Related]
35. Interstitial cells subjacent to the entorhinal region expressing somatostatin-28 immunoreactivity are susceptible to development of Alzheimer's disease-related cytoskeletal changes. van de Nes JA; Sandmann-Keil D; Braak H Acta Neuropathol; 2002 Oct; 104(4):351-6. PubMed ID: 12200620 [TBL] [Abstract][Full Text] [Related]